Injectable HIV treatment offers hope to Ugandan patients

KAMPALA - Ever since Gerald Muwonge tested positive for HIV eight years ago, keeping his viral load in check has meant carrying around vials of pills for his daily treatment regimen while dodging the stigma this could mean for a gay man in Uganda. But he hopes that could soon change thanks to an injectable treatment that only needs to be taken once every two months. In October of last year, about 200 patients in the east African country began a trial of a World Health Organization-approved injection containing the drugs cabotegravir, or CAB-LA, and rilpivirine. Results are due in 2024. The treatment, developed by British drugmaker GlaxoSmithKline, is the first non-pill option against HIV, and studies have shown it even outperforms the efficacy of oral pills. "These drugs, you have to take them every day, and if you are taking them at exactly 9 a.m., it should be that way until you die," said Muwonge, a 27-year-old activist for lesbian, gay, bisexual, transgender and intersex (LGBTI) rights. He says the strict regimen of taking the pills messes with his head. Muwonge, who is not among the patients in the trial, said the new injectable treatment option could help to reduce the stigma HIV patients suffer, particularly gay men like himself. Homosexuality is illegal in Uganda, and gay people often face arrest, ostracism and violence at the hands of law enforcement or local vigilantes. Many who have HIV have not come out to friends, family members and co-workers and prefer to hide that they have an illness that disproportionately affects the LGBI community. The GSK treatment secured U.S. approval late last year and was endorsed this year by the World Health Organization. GSK struck a deal in July to allow low-cost generic versions to be used in the developing world but said the first generics will potentially only become available in 2026 because of regulatory requirements for manufacture and use. In the interim, GSK said it was working on providing governments the regimen free of charge to run studies. Trials are also taking place in Kenya and South Africa. William Tamale, a manager of the injectable antiretroviral treatment programme at Uganda's Joint Clinical Research Centre, said the drugs were "very promising." The JCRC was chosen to administer the trial of the injectable drugs and Tamale is in charge of that progamme in Uganda, where at least 1.4 million people live with HIV/AIDS. (Writing by Elias Biryabarema; Editing by Aaron Ross and Jane Merriman)

Injectable HIV treatment offers hope to Ugandan patients

DISCOVER MORE

Somalia's drought killed 43,000 last year, half under five

Nigerian ruling party keeps powerful Lagos post after tense local polls

South African protesters march amid heavy security

What time's kickoff? Four hour delay baffles Libya's Al-Akhdar

Australian firm plans 300 MW green ammonia plant in Kenya

Erdogan and Egypt's Sisi to meet: Turkish minister

Ethiopia dismisses Egypt's fresh warning on Blue Nile dam

Nigeria counts local election votes in shadow of contested poll

Can GCC banks manage contagion risk from Silicon Valley Bank collapse?

Saudi National Bank says no impact on growth plans from Credit Suisse

SNB offers $100bln to help UBS Group take over Credit Suisse

Oman reveals list of 103 countries whose citizens can visit visa free

Saudi PIF-owned SRC buys home loans worth $1.33bln from Al Rajhi Bank

Tanzania probes mystery illness after five die

Congolese doctor picked to head Africa CDC

$20mln OPEC Fund loan to boost cardiovascular healthcare in Uganda

Morocco’s Laprophan, China’s Sinopharm sign healthcare cooperation pact

INTERVIEW: iSono Health transforms breast cancer diagnosis and treatment with ATUSA scanner

LATEST VIDEO

VIDEO: Saudi crown prince launches new national airline

ZAWYA COVERAGE

ACWA Power CEO Paddy Padmanathan retires after 18 years of service

Dubai’s DEWA, JPMorgan tackle ways to cooperate in green, sustainable financing

Saudi ACWA Power signs deals to invest $2.5bln in green projects in Uzbekistan

Healthcare expenditure in GCC to reach $135.5bln in 2027

Amazon to cut 9,000 jobs in second round of layoffs

India's strong corporate debt profile key to macroeconomic stability

Somalia's drought killed 43,000 last year, half under five

Mideast Stocks: Most Gulf bourses end lower as oil prices drop; Egypt rises

UAE President, Romanian President review bilateral relations, regional issues

THE BRI REPORT

China is reshaping the Belt and Road Initiative ahead of a post-pandemic era

DISCOVER MORE

LATEST VIDEO

ZAWYA NEWSLETTERS

ZAWYA COVERAGE